Bionaturis Group takes part one more year in the Small and Medium-Size Companies Forum -MedCap-, on May 31st and June 1st in Madrid.

Bionaturis Group CEO, Victor Infante, is the person in charge of presenting the latest milestones achieved by the company, among with we can highlight the establishment of the subsidiary BNT China Biosciences in China, the signing of a contract with the US National Institute of Environmental Health (NIEHS) and the recent acquisition of the company ZIP Solutions, that has signed a co-development and exclusive license agreement with a leading multinational company for the final development and market of Splittera® technology.

Thanks to these latest operations, Bionaturis Group continues positioning as a reference company in its area, through its four companies and two subsidiaries with presence in Europe, USA and Asia. The Group offers premium services and products for human and animal health.

In this edition of the MedCap Forum, Bionaturis Group takes part in both ‘One to One’ meetings and the Discovery Meeting, with a lecturer in the afternoon on May, 31st, available here.

About the MedCap

The 11nd MEDCAP Forum gathers the main Small and Medium Size Companies listed on the Spanish Stock Exchange Market as well as institutional investors, brokers and financial analysts. The program includes both sectorial and general round tables, as well as the possibility of holding ‘One to One’ meetings. The main goal of the event is to stimulate the liquidity and founding of these companies.

About Bionaturis Group

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT). In addition to this new acquisition, Bionaturis Group has other two locations in Spain (Bionaturis and Biobide) and two subsidiaries in the USA and China.